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Cystic Fibrosis (CF) involves the upper airways with chronic 
rhinosinusitis (CRS) causing nasal congestion, rhinorrhea, mouth 
breathing, facial pain, and olfactory dysfunction. Twelve to 71% 
of CF patients report smelling alterations impacting nutrition and 
quality of life. The aim was to study olfaction performance in CF 
patients with CRS that worsens quality of life. One hundred and 
twenty-one subjects were enrolled in this study. Seventy-one had 
CF and underwent ear, nose, and throat evaluation with nasal 
endoscopy, SNOT-22, VAS and “Sniffin’ Sticks”. Fifty subjects 
were age-matched with healthy controls. All 71 CF patients were 
affected by CRS; 59/71 (83.1%) had CRS without nasal polyps 
and 12/71 (16.9%) had CRS with early nasal polyps. None of the 
50 controls had CRS. Total SNOTT-22 mean values in the 71 CF 
patients was 38.10 ± 21.08 pts. If considering only the 59 CF 
patients without nasal polyps the SNOTT-22 mean value was 
36.76 ± 21.52 pts. Moreover, based on the VAS scores, the degree 
of nasal symptoms was classified as mild for facial pain, smell 
alteration, nasal discharge, and sneezing and resulted in moderate 
symptoms for nasal blockage and headache. Among the CF 
patients, 55/71 (76.5%) declared normosmia while the smelling 
ability assessed by “Sniffin’ Sticks” showed that only 4/71 
(5.63%) were normosmic, 58 (81.69%) were hyposmic, and 9 
(12.68%) were anosmic. In the controls 41(82%) were 
normosmic, 9 (18%) were hyposmic, and none were reported 
anosmia (p < 0.001). The study confirms that most CF patients 
have a relevant olfactory impairment, although only a low 
percentage declare it. A careful evaluation with simple and rapid 
tests helps to select the patients that may benefit from specific 
therapies. 
